Enhanced Specialized Variations & Niche Solutions Technical Implementation

Publication ID: 24-11858931_0004_PTD

Published: November 07, 2025

Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Enhanced Specialized Variations & Niche Solutions Technical Implementation,” Published Technical Disclosure No. 24-11858931_0004_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858931_0004_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,931.

Summary of the Inventive Concept

An improved approach to specialized variations & niche solutions that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but specialized variations & niche solutions presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements specialized variations & niche solutions enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting specialized variations & niche solutions improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from specialized variations & niche solutions enhancements.

CPC Classifications

Section	Class	Group
C	C07	C07D471/04
C	C07	C07D519/00

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical chemistry, specifically medicinal compounds targeting fibrotic diseases and integrin modulation, with expertise in organic synthesis, drug design, and molecular pharmacology

Person of Ordinary Skill (PHOSITA) Profile

A researcher or pharmaceutical scientist with advanced degree (PhD) in medicinal chemistry, experienced in designing integrin inhibitors, understanding structure-activity relationships, and developing therapeutic compounds for fibrotic conditions

Obviousness Rationale

A PHOSITA would recognize that the PTD represents predictable variations on the source patent's core technical approach of developing integrin-modulating compounds for fibrotic disease treatment. The disclosed variations demonstrate standard engineering design choices and incremental improvements that would be expected in pharmaceutical compound development. The technical modifications represent routine optimization strategies within the established framework of the original patent's therapeutic method.

Obvious Combinations & Variations

Source Patent Element

Compound targeting αVβ6 integrin for fibrotic disease treatment

PTD Variation

Extending compound design to include additional integrin subunit variations and niche therapeutic applications

Obviousness Reasoning

Known technique of systematic molecular modification to expand therapeutic targeting, with predictable results in drug development

Source Patent Element

Method of inhibiting TGF-β activation through specific molecular compounds

PTD Variation

Implementing enhanced molecular configurations to improve integrin interaction and cellular signaling modulation

Obviousness Reasoning

Routine optimization of molecular structure to improve pharmacological performance, representing standard pharmaceutical engineering approach

Source Patent Element

Treatment of liver fibrosis through integrin inhibition

PTD Variation

Expanding therapeutic approach to include specialized variations for different fibrotic disease manifestations

Obviousness Reasoning

Finite set of known fibrotic conditions with predictable molecular intervention strategies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11858931, a Person Having Ordinary Skill In The Art would find the technical variations disclosed herein to be obvious extensions of the prior art, representing routine optimization and predictable variations within the established pharmaceutical compound design framework. The disclosed technical solution would render obvious any subsequent patent claims attempting to monopolize these straightforward molecular engineering approaches.

Original Patent Information

Patent Number	US 11,858,931
Title	Amino acid compounds with unbranched linkers and methods of use
Assignee(s)	Pliant Therapeutics, Inc.